Drugs and Pharmaceuticals
Free News Articles Category: Drugs and Pharmaceuticals Industry News Articles
Belvidere Pharmacy Earns Top Accreditation Honor, Once Again
freeNewsArticles Story Summary: For the second time in its history, Belvidere Pharmacy of North Plainfield has secured the coveted Pharmacy Compounding Accreditation Board’s (PCAB) Seal of Accreditation. Registered in New York, New Jersey and Connecticut, Belvidere was the first and is still the only accredited PCAB pharmacy in the New York metro area. It has held this distinction since 2007….
Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy
freeNewsArticles Story Summary: Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company’s lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant….
Reaction Biology Receives NCI Grant Award for Epigenetic Platform
freeNewsArticles Story Summary: MALVERN, Pa. — Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC’s methyltransferase screens from 14 to 35 or more….
Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents
freeNewsArticles Story Summary: SAN MARINO, Calif. — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances….
Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)
freeNewsArticles Story Summary: SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled ‘Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma’ at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA….
Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
freeNewsArticles Story Summary: SAN MARINO, Calif. — Epeius Biotechnologies Corporation today announces the clinical results of the study entitled ‘A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol’ at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study….
Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
freeNewsArticles Story Summary: SAN MARINO, Calif. — Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled ‘Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer’ (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA….
Epeius Biotechnologies Receives Notice of Patent Allowance for Tumor-Targeted Cancer Vaccines
freeNewsArticles Story Summary: SAN MARINO, Calif. — Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe….
Reports Indicate Fluramene to Provide Earlier and Easier Detection of Ocular Surface Disorders
freeNewsArticles Story Summary: EUGENE, Ore. — Noble Vision Group, LLC, a research and development organization today announced reports of favorable results for the topical dye formulation, Fluramene(TM), among leading eye care professionals. Fluramene, the proprietary Fluorescein Sodium and Lissamine Green dye combination is a sterile solution packaged in a 15mL bottle with a control tip dropper. The benefits of both dyes have been studied comprehensively and are well reported as diagnostic tools used independent of each other….
Epeius Biotechnologies Corporation Expands its Rexin-G Production Facilities in Southern California
freeNewsArticles Story Summary: SAN MARINO, Calif. — Epeius Biotechnologies announces the completion of the design engineering and construction phase of a state-of-the-art Vector Production Unit (VPU) for the commercial manufacturing of its advanced targeted genetic medicines. In accordance with an FDA Critical Path initiative, which encourages innovation and the implementation of new technological advances in quality control, the Epeius VPU is poised to launch the large-scale production of targeted genetic medicine into the 21st century….